AdV disease and GVHD status before and after ACT
| . | No. of patients/No. ofevaluable patients . |
|---|---|
| Site of local infection | |
| Stool | 29 |
| Urine | 6 |
| Nasopharyngeal fluid | 9 |
| Bronchoalveolar lavage | 1 |
| Adenoviral disease | 24 |
| Symptoms of AdV disease | |
| Diarrhea | 19 |
| Nephritis | 4 |
| Hepatitis | 6 |
| Cystitis | 4 |
| Pneumonia | 5 |
| Encephalitis | 1 |
| Course of AdV infection after ACT | |
| Viral clearance in patients with in vivo T-cell expansion | 12/14 |
| Responders*† | 21/30 |
| With final clearance of AdV in blood‡ | 14/21 |
| Without final clearance of viremia | 3/21 |
| With negative viremia at transfer§ | 4/21 |
| Nonresponders|| | 8/30 |
| GVHD prophylaxis at ACT | |
| Cyclosporine | 11 |
| Mycophenolate mofetil | 13 |
| Steroids | 16 |
| None | 5 |
| GVHD status prior to ACT | |
| No GVHD | 23 |
| Grade 1-2 | 2 |
| Grade 3-4 | 4 |
| Chronic GVHD | 1 |
| Early onset of GVHD after ACT† | |
| No onset of GVHD | 27 |
| Grade 1 | 2 |
| Grade 2-4 | 0 |
| . | No. of patients/No. ofevaluable patients . |
|---|---|
| Site of local infection | |
| Stool | 29 |
| Urine | 6 |
| Nasopharyngeal fluid | 9 |
| Bronchoalveolar lavage | 1 |
| Adenoviral disease | 24 |
| Symptoms of AdV disease | |
| Diarrhea | 19 |
| Nephritis | 4 |
| Hepatitis | 6 |
| Cystitis | 4 |
| Pneumonia | 5 |
| Encephalitis | 1 |
| Course of AdV infection after ACT | |
| Viral clearance in patients with in vivo T-cell expansion | 12/14 |
| Responders*† | 21/30 |
| With final clearance of AdV in blood‡ | 14/21 |
| Without final clearance of viremia | 3/21 |
| With negative viremia at transfer§ | 4/21 |
| Nonresponders|| | 8/30 |
| GVHD prophylaxis at ACT | |
| Cyclosporine | 11 |
| Mycophenolate mofetil | 13 |
| Steroids | 16 |
| None | 5 |
| GVHD status prior to ACT | |
| No GVHD | 23 |
| Grade 1-2 | 2 |
| Grade 3-4 | 4 |
| Chronic GVHD | 1 |
| Early onset of GVHD after ACT† | |
| No onset of GVHD | 27 |
| Grade 1 | 2 |
| Grade 2-4 | 0 |
Defined as patients with significant reduction (>1 log) of viremia after ACT (straight or transient).
Course of viremia and onset of GVHD is not evaluable for patient 1 because of death 2 days after ACT.
Patient 10 had AdV-negative blood at ACT but developed viremia thereafter with consequent re-clearance of the viral load and is therefore classified as responder with final clearance of viremia.
Patients with viremia-negative blood at ACT who showed clearance of AdV at other sites of infection (stool, urine, or nasopharyngeal fluid).
Defined as patients with persistent or increasing viral loads or with negative viremia at ACT and without virus clearance at other sites of infection.